Related references
Note: Only part of the references are listed.Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview
Clotilde Sparano et al.
ENDOCRINE-RELATED CANCER (2021)
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Christine Dierks et al.
THYROID (2021)
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J. Wirth et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force
Keith C. Bible et al.
THYROID (2021)
Response to immunotherapy in a patient with anaplastic thyroid cancer A case report
Luming Zheng et al.
MEDICINE (2021)
Management of Anaplastic and Recurrent Differentiated Thyroid Cancer Indications for Surgical Resection, Molecular Testing, and Systemic Therapy
Maria E. Cabanillas et al.
NEUROIMAGING CLINICS OF NORTH AMERICA (2021)
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale
Pia Adam et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Novel treatments for anaplastic thyroid carcinoma
Silvia Martina Ferrari et al.
GLAND SURGERY (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Recent advances in the management of anaplastic thyroid cancer
Simone De Leo et al.
THYROID RESEARCH (2020)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
Jennifer R. Wang et al.
THYROID (2019)
A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
Shunji Takahashi et al.
FUTURE ONCOLOGY (2019)
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Liisa Chang et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects
Kenneth G. Liu et al.
ONCOTARGET (2017)
Interaction of Molecular Alterations With Immune Response in Melanoma
Robert A. Szczepaniak Sloane et al.
CANCER (2017)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Panayiotis Savvides et al.
THYROID (2013)
A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
R. C. Smallridge et al.
CLINICAL ONCOLOGY (2010)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches
C Are et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Cytological diagnosis of paucicellular variant of anaplastic carcinoma of thyroid: report of two cases
AH Deshpande et al.
CYTOPATHOLOGY (2001)
Paucicellular variant of anaplastic thyroid carcinoma: Report of two cases
JC Canos et al.
ENDOCRINE PATHOLOGY (2001)